AbbVie advances cosmetic indication for jawline contouring as regulatory pathway accelerates.
The FDA has accepted AbbVie's supplemental Biologics License Application (sBLA) for BOTOX in masseter hypertrophy—the cosmetic indication for jawline prominence reduction. The acceptance signals the agency's preliminary view that the application is complete and substantively reviewable, clearing a key regulatory hurdle.
Masseter BOTOX represents a meaningful expansion of the toxin's cosmetic label and a direct competitive response to Revance's Daxxify, which already carries the indication. The masseter market—driven by younger demographics and aesthetic demand for facial contouring—has grown faster than traditional glabellar and lateral canthal uses, and label approval will likely accelerate adoption among practices seeking new revenue streams.
FDA accepts BOTOX masseter sBLA; approval clears regulatory path.
Practice owners should monitor the approval timeline and label language closely. If approved, the indication will require patient education and dosing precision (masseter injections typically demand 20–50 units per side, higher than brow work), and reimbursement coding will matter for any medical necessity claims in jaw-clenching or TMJ-related cases.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
